hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06331650 id: CROC202314 briefTitle: A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer overallStatus: RECRUITING date: 2023-08-09 date: 2025-08 date: 2025-10 date: 2024-03-26 date: 2024-03-26 name: Guangzhou Institute of Respiratory Disease class: OTHER briefSummary: To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as the first-line treatment for patients with STK11 mutated advanced or postoperative recurrent non-small cell lung cancer (NSCLC). conditions: Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: cadonilimab measure: Safety assessments and ORR sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Guangzhou Medical University status: RECRUITING city: Guangdong state: Guangzhou zip: 510000 country: China name: zhou chegnzhi, doctor role: CONTACT phone: 13560351186 email: doctorzcz@163.com hasResults: False
nctId: NCT06331637 id: 3782 briefTitle: Outcomes of Transanal Tran-section and Single-stapled (TTSS) Ileal Pouch-Anal Anastomosis acronym: TTSS-Pouch overallStatus: NOT_YET_RECRUITING date: 2024-07-31 date: 2026-07-31 date: 2026-12-31 date: 2024-03-26 date: 2024-03-26 name: Istituto Clinico Humanitas class: OTHER briefSummary: This study aims to compare the functional and surgical outcomes of Ulcerative Colitis (UC) patients undergoing Transanal Transection and Singl-Stapled (TTSS) versus Double-stapled Ileal Pouch-Anal Anastomosis (IPAA) conditions: Ulcerative Colitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 174 type: ESTIMATED name: Transanal Transection and Single-Stapled anastomosis (TTSS) name: Double-stapled anastomosis measure: Pouch Function Score (PFS) measure: Pouch Function Score (PFS) measure: Pouch Function Score (PFS) measure: Postoperative complications measure: Anastomotic leak measure: Patients fit for stoma closure measure: Healthcare costs measure: Rectal cuff lenght measure: Pouch complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Humanitas Research Hospital city: Rozzano state: MI zip: 20089 country: Italy name: Annalisa Maroli, PhD role: CONTACT phone: 02 8224 7776 phoneExt: 0039 email: colorapp@humanitas.it name: Stefano De Zanet, MS role: CONTACT phone: 02 8224 4623 phoneExt: 0039 email: colorapp@humanitas.it lat: 45.38193 lon: 9.1559 hasResults: False
nctId: NCT06331624 id: GRI-0621-IPF-02 briefTitle: Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF overallStatus: RECRUITING date: 2024-03 date: 2025-01 date: 2025-01 date: 2024-03-26 date: 2024-03-26 name: GRI Bio Operations, Inc. class: INDUSTRY briefSummary: This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An interim analysis will be performed when 24 subjects complete 6 weeks of treatment (approximately 8 placebo subjects). conditions: Idiopathic Pulmonary Fibrosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 36 type: ESTIMATED name: Tazarotene (GRI-0621) name: Placebo measure: Safety and Tolerability of oral GRI-0621 measure: Change from baseline biomarkers measure: Plasma concentrations of GRI-0621 measure: Pharmacodynamics of GRI-0621 in blood (Study Population) measure: Pharmacodynamics of GRI-0621 in BAL fluid (Optional Sub-Study) measure: Exploratory - Pulmonary Function sex: ALL minimumAge: 40 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Newport Native MD, Inc. status: RECRUITING city: Newport Beach state: California zip: 92663 country: United States name: Brandon Vu role: CONTACT phone: 949-791-8599 email: Brandon@newportnativemd.com lat: 33.61891 lon: -117.92895 facility: Southeastern Research Center status: RECRUITING city: Winston-Salem state: North Carolina zip: 27103 country: United States name: Karen McCutcheon role: CONTACT phone: 336-659-8414 email: kmccutcheon@southeasternresearchcenter.com lat: 36.09986 lon: -80.24422 hasResults: False
nctId: NCT06331611 id: Motor briefTitle: MONITORING NEUROMUSCULAR BLOCK IN PAEDIATRIC ANAESTHESIA acronym: MOTOR overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2025-12-31 date: 2024-03-26 date: 2024-03-27 name: Istituto Giannina Gaslini class: OTHER briefSummary: To date there is still little scientific evidence regarding neuromuscular block monitoring in pediatric anesthesia and indications for safe reversal. Although the use of rocuronium and sugammadex is becoming wide, qualitative monitoring or clinical practice are applied instead of quantitative monitoring (acceleromyography-electromyography EMG). The use of neuromuscular monitoring leads to better control of intraoperative paralysis, proper timing of extubation, and reduced risk of residual postoperative paralysis-paralysis (PORC) and related complications.
* the need to administer additional doses of sugammadex. A prospective RCT. Patients will be divided into two study groups; in the first group, quantitative neuromuscular monitoring based on electromyography (EMG) will be used, while in the second group, the same monitoring will be applied but covered (blinded to the anesthetist) and the pharmacological strategy is based exclusively on the clinical practice All children aged between 2 months and 6 years, scheduled to undergo elective non-cardiac surgical procedures, lasting approximately from one to two hours(anesthesia time), with general anesthesia and tracheal intubation receiving a non-depolarizing blockade agent.
Demographics and baseline characteristics with mean, median, standard deviation, and range (minimum, maximum) will generated for each arm. Subject disposition, including the number of subjects withdrawn or discontinued from the study, for each arm will summarized. The study will follow the CONSORT guidelines for statistical analysis and reporting. Chi squared test or Fisher's exact test and Student's t-test or Mann Whitney test will applied to categorical and continuous data, respectively, with a significance level of 5% by two-sided test. Statistical analysis was performed using SPSS software (ver. 21.0) (IBM, Armonk, NY, USA). conditions: Anesthesia,General conditions: Neuromuscular Blockade conditions: Tracheal Intubation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 200 type: ESTIMATED name: TOF monitoring measure: Sugammadex administration sex: ALL minimumAge: 2 Years maximumAge: 12 Years stdAges: CHILD hasResults: False
nctId: NCT06331598 id: ML43332 id: 2022-003708-33 type: EUDRACT_NUMBER briefTitle: A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) acronym: IMperator overallStatus: RECRUITING date: 2024-05-30 date: 2028-10-20 date: 2029-09-20 date: 2024-03-26 date: 2024-04-17 name: Hoffmann-La Roche class: INDUSTRY briefSummary: This study is being conducted to evaluate efficacy parameters (disease free survival \[DFS\] and overall survival \[OS\]) of atezolizumab and atezolizumab in combination with tiragolumab in TMB-H or MSI-H as adjuvant treatment after standard radical intended treatment in participants with intermediate-high risk of recurrence. conditions: Solid Tumors studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Atezolizumab name: Tiragolumab measure: Disease Free Survival (DFS) Rate at 24 Months measure: DFS Rate at 36, 48 and 60 Months measure: OS (Overall Survival) measure: Percentage of Participants With Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitari Vall dHebron; Oncology status: RECRUITING city: Barcelona zip: 08035 country: Spain lat: 41.38879 lon: 2.15899 facility: Hospital Universitario Virgen; Servicio de Oncologia status: RECRUITING city: Sevilla zip: 41013 country: Spain lat: 37.38283 lon: -5.97317 hasResults: False
nctId: NCT06331585 id: KY-2024004 briefTitle: Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy overallStatus: WITHDRAWN date: 2024-03-18 date: 2025-03-18 date: 2026-03-18 date: 2024-03-26 date: 2024-04-25 name: Hetian District People's Hospital class: OTHER briefSummary: The purpose of this phase Ⅱ trial was to investigate the effect of low-dose radiotherapy (LDRT) on the tumor immune microenvironment (TME) in oligometastasis, oligoprogression, and oligopersistence of non-small cell lung cancer (NSCLC) after immunotherapy. At least 20 participants will be enrolled in this study. All will take part at Hetian District People's Hospital. conditions: Low-dose Radiotherapy conditions: Tumor Microenvironment conditions: Non-Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 0 type: ACTUAL name: low dose radiotherapy measure: Analysis of the tumor immune microenvironment measure: Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measurement of Safety and Tolerability of Low Dose Radiotherapy measure: Progression Free Survival (PFS) measure: Overall Survival (OS) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hetian District People's Hospital city: Hetian state: Xinjiang Uygur Autonomous Region zip: 848000 country: China hasResults: False
nctId: NCT06331572 id: 1stChongqingMU-TRD briefTitle: Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression overallStatus: COMPLETED date: 2021-08-01 date: 2021-10-25 date: 2023-12-20 date: 2024-03-26 date: 2024-03-26 name: First Affiliated Hospital of Chongqing Medical University class: OTHER briefSummary: This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD. conditions: Psychiatric Disorder conditions: Major Depressive Disorder conditions: Metabolic Disorder studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 162 type: ACTUAL name: 17-HAMD measure: 17 items Hamilton Depression Scale measure: Hamilton Anxiety Scale sex: ALL minimumAge: 12 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: The First Affiliated Hospital of Chongqing Medical University city: Chongqing state: Province zip: 400000 country: China lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06331559 id: SIM0501-101 briefTitle: Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors overallStatus: RECRUITING date: 2024-03-19 date: 2026-06-30 date: 2027-12-31 date: 2024-03-26 date: 2024-04-02 name: Jiangsu Simcere Pharmaceutical Co., Ltd. class: INDUSTRY name: Shanghai Xianxiang Medical Technology Co., Ltd. briefSummary: This is an open-label, multicenter Phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0501 in participants with advanced solid tumors. The trial consists two parts, Part 1 for SIM0501 monotherapy and Part 2 for SIM0501 in combination with olaparib. In both parts, SIM0501 with/without olaparib will be administered until disease progression or the investigator determines that continuation of the study drug would not benefit, or there is intolerable toxicity, or the participant or legal representative voluntarily requests withdrawal, or the trial is terminated. conditions: Advanced Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 176 type: ESTIMATED name: SIM0501 Tablets name: SIM0501 Tablets name: SIM0501 in combination with olaparib name: SIM0501 in combination with olaparib measure: Dose-limiting toxicity (DLT) measure: Adverse events will be evaluated according to the CTCAE v5.0 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shandong Cancer Hospital status: RECRUITING city: Jinan state: Shandong zip: 250117 country: China name: Jinming Yu role: CONTACT phone: 0531-67626971 email: sdyujinming@126.com lat: 36.66833 lon: 116.99722 hasResults: False
nctId: NCT06331546 id: IRB300004693 id: R01DK137784 type: NIH link: https://reporter.nih.gov/quickSearch/R01DK137784 briefTitle: Gut Oxalate Absorption in Calcium Oxalate Stone Disease overallStatus: RECRUITING date: 2024-05-01 date: 2030-12-31 date: 2031-12-31 date: 2024-03-26 date: 2024-04-03 name: University of Alabama at Birmingham class: OTHER name: University of Texas Southwestern Medical Center name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased absorption of dietary oxalate, which would lead to increased urinary excretion of oxalate.
* collect urine, blood, stool and breath sample during the fixed diets and the soluble oxalate test conditions: Kidney Stone conditions: Kidney Calculi conditions: Urolithiasis conditions: Urolithiasis, Calcium Oxalate conditions: Nephrolithiasis conditions: Nephrolithiasis, Calcium Oxalate conditions: Oxalate Urolithiasis conditions: Oxaluria conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 80 type: ESTIMATED name: Low-oxalate diet name: High-oxalate diet name: soluble oxalate gut absorption test measure: Net Gastrointestinal absorption of food-bound oxalate measure: Absorption of soluble 13C2-oxalate measure: Estimated endogenous oxalate synthesis (oxalate mg/day) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama at Birmingham status: RECRUITING city: Birmingham state: Alabama zip: 35294 country: United States name: Sonia Fargue, PhD role: CONTACT phone: 205-975-6932 email: kidneystone@uabmc.edu name: Research Coordinator role: CONTACT phone: 205-9345712 email: kidneystone@uabmc.edu name: Sonia Fargue, PhD role: PRINCIPAL_INVESTIGATOR lat: 33.52066 lon: -86.80249 facility: UTSW status: ACTIVE_NOT_RECRUITING city: Dallas state: Texas zip: 75390 country: United States lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06331533 id: IstanbulTRH1 briefTitle: Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea overallStatus: COMPLETED date: 2022-11-01 date: 2023-05-01 date: 2023-06-01 date: 2024-03-26 date: 2024-03-29 name: Istanbul Training and Research Hospital class: OTHER_GOV briefSummary: Investigation of the effectiveness of intradermal botulinum toxin A treatment in the treatment of erythematotelangiectatic rosacea (ETR) using clinical, biophysical, dermatoscopic and videocapillaroscopy. conditions: Erythematotelangiectatic Rosacea studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Randomized, split face, efficacy study primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Botulinum toxin will be injected into one randomly selected half of the face, and placebo will be injected into the other half of the face. The patient will not know which half of the face was treated. An independent, blinded dermatologist will evaluate the results of the treatment. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 30 type: ACTUAL name: Botulinum toxin A name: Placebo measure: Assessment of erythema with Clinician's Erythema Assessment scale measure: Evaluation of erythema using mexameter measure: Evaluation of erythema by dermatoscopy measure: Evaluation of the change in vascular structure using videocapillaroscopy sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Istanbul Training and Research Hospital city: Istanbul zip: 34098 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06331520 id: Desineo briefTitle: NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2026-05-01 date: 2024-03-26 date: 2024-03-26 name: Fudan University class: OTHER briefSummary: The objective of this Prospective, randomized, non inferiority phase III trial is to confirm the efficacy and saftey of dexamethasone-sparing combined with netupitant/palonostron and olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. conditions: Chemotherapy-induced Nausea and Vomiting conditions: Highly Emetogenic Chemotherapy studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 627 type: ESTIMATED name: Netupitant / Palonosetron Oral Capsule [Akynzeo] name: Olanzapine name: Dexamethasone Oral measure: Percentage of patients with complete response (CR) measure: Percentage of Patients With CR (acute and delayed) measure: Percentage of patients with overall complete protection(OCP) measure: Percentage of patients with overall total control (OTC) measure: incidence of adverse events measure: quality of life questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06331507 id: HUM00176904 briefTitle: Refinement and Assessment of New MRI Technologies for Cardiovascular Exams Using the Phillips CMR Patch overallStatus: TERMINATED date: 2021-09-02 date: 2023-06-29 date: 2023-06-29 date: 2024-03-26 date: 2024-03-26 name: University of Michigan class: OTHER name: Philips Health Care briefSummary: This study is being done to improve image quality and provide the collaborator with feedback on wide band imaging in patients with cardiac implantable electronic devices (CIED). conditions: Cardiomyopathies studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 292 type: ACTUAL name: CMR patch measure: Scan speed: sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Michigan Medicine - University of Michigan city: Ann Arbor state: Michigan zip: 48109 country: United States lat: 42.27756 lon: -83.74088 hasResults: False
nctId: NCT06331494 id: SICAS briefTitle: Efficacy of Butylphthalide on Symptomatic Atherosclerotic Stenosis in Middle Cerebral Artery acronym: SICAS overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-05-31 date: 2026-08-31 date: 2024-03-26 date: 2024-03-26 name: First Affiliated Hospital, Sun Yat-Sen University class: OTHER briefSummary: Ischemic stroke with high incidence, mortality, disability and recurrence rate, has become the leading threat to the health worldwide. Intracranial atherosclerotic stenosis (ICAS) is commonly associated with ischemic stroke, especially in Chinese residents. Patients with severe ICAS are subject to a very high risk of recurrent stroke events, despite best medical therapy available. Unstable or complex atherosclerotic plaques can lead to plaque ruptures and distal embolisms, thereby increasing the risk of ischemic stroke recurrence. Studies have shown that activation of inflammatory states may play a driving role in the formation and development of atherosclerosis. So far, it remains unclear which are the best treatments for this condition, especially for high-risk patients. Dl-3-n-butylphthalide (NBP) is a Class I novel drug independently developed in China and was officially approved for use in acute ischemic stroke. Preclinical data showed that NBP can act multiple effects of anti-inflammation, antioxidation and anti-apoptosis by suppressing pro-inflammatory factors and upregulating the expression of anti-inflammatory factors. It is still undetermined whether combined therapy with NBP could enhance the curative effect of intracranial atherosclerosis. The primary purpose of this trial is to evaluate the efficacy of butylphthalide in reducing the degree of arterial stenosis and stabilizing plaques in patients with severe symptomatic middle cerebral artery stenosis. conditions: Ischemic Stroke, Acute conditions: Intracranial Atherosclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 140 type: ESTIMATED name: Butylphthalide name: Placebo measure: Changes in stenosis degree in the responsible artery measure: Stroke recurrence measure: Change in plaque volumes the responsible artery measure: Changes in hemorrhage and enhancement volumes of atherosclerotic plaque in the responsible artery measure: Changes in National Institutes of Health Stroke Scale (NIHSS) measure: Proportion of patients with modified Rankin Scale score (mRS) 0-2 measure: Change in the value of cerebral blood flow (CBF) in the responsible artery territory measure: Change in concentrations of serum lipid profiles sex: ALL minimumAge: 55 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital, Sun Yat-sen University city: Guangzhou state: Guangdong zip: 510080 country: China name: Jinsheng Zeng role: CONTACT phone: +8613322800657 email: zengjs@pub.guangzhou.gd.cn name: Shihui Xing role: CONTACT phone: +8613602755395 email: xingshih@mail.sysu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06331481 id: 0005-22-HYMC briefTitle: The Effect of Over Weight on Oocytes Quality in IVF Patients acronym: IVF overallStatus: ACTIVE_NOT_RECRUITING date: 2022-02-01 date: 2023-12-31 date: 2024-07 date: 2024-03-26 date: 2024-03-26 name: Hillel Yaffe Medical Center class: OTHER_GOV briefSummary: Obesity is an increasing worldwide problem and a risk factor for many diseases. The effect of obesity on female fertility has been extensively tested. Obese women have increased time to pregnancy and remain subfertile even in the absence of ovulatory dysfunction. They present with higher incidence of infertility compared to normal weight women.
This study is prospective observational cohort study performed between February 2022 until June 2022 in a single university-affiliated hospital. conditions: IVF conditions: Overweight studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ACTUAL name: Fullicular fluid for cytology and biocemical analysis measure: Impact of obesity on oocyte's mtDNA expression in Cumulus Cells measure: Impact of obesity on oocyte quality through levels of protein BMP-15 measure: Impact of obesity on oocyte quality through levels of protein HSPG2 measure: Impact of obesity on fertilization and pregnancy rates through analysis of mtDNA expression measure: Impact of obesity on fertilization and pregnancy rates through levels of protein BMP-15 measure: Impact of obesity on fertilization and pregnancy rates through levels of protein HSPG2 sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Hillel Yaffe Medical Center - IVF Unit city: Hadera zip: 38100 country: Israel lat: 32.44192 lon: 34.9039 hasResults: False